- Home
- BCG vs ITRM Comparison
BCG vs ITRM Comparison
Compare BCG & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- ITRM
- Stock Information
- Founded
- BCG 2016
- ITRM 2015
- Country
- BCG United States
- ITRM Ireland
- Employees
- BCG N/A
- ITRM N/A
- Industry
- BCG
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- ITRM Health Care
- Exchange
- BCG Nasdaq
- ITRM Nasdaq
- Market Cap
- BCG 45.6M
- ITRM 49.5M
- IPO Year
- BCG N/A
- ITRM 2018
- Fundamental
- Price
- BCG $2.58
- ITRM $1.75
- Analyst Decision
- BCG
- ITRM Strong Buy
- Analyst Count
- BCG 0
- ITRM 1
- Target Price
- BCG N/A
- ITRM $5.00
- AVG Volume (30 Days)
- BCG 76.8K
- ITRM 1.6M
- Earning Date
- BCG 11-14-2024
- ITRM 11-14-2024
- Dividend Yield
- BCG N/A
- ITRM N/A
- EPS Growth
- BCG N/A
- ITRM N/A
- EPS
- BCG N/A
- ITRM N/A
- Revenue
- BCG $161,721,000.00
- ITRM N/A
- Revenue This Year
- BCG N/A
- ITRM N/A
- Revenue Next Year
- BCG N/A
- ITRM N/A
- P/E Ratio
- BCG N/A
- ITRM N/A
- Revenue Growth
- BCG N/A
- ITRM N/A
- 52 Week Low
- BCG $1.85
- ITRM $0.81
- 52 Week High
- BCG $16.61
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- ITRM 45.98
- Support Level
- BCG N/A
- ITRM $1.78
- Resistance Level
- BCG N/A
- ITRM $1.95
- Average True Range (ATR)
- BCG 0.00
- ITRM 0.30
- MACD
- BCG 0.00
- ITRM -0.10
- Stochastic Oscillator
- BCG 0.00
- ITRM 0.00
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.